European Product Approval

Advanced Medical Solutions Grp PLC
20 June 2006


For immediate release                                               20 June 2006


                      Advanced Medical Solutions Group plc
                            ('AMS' or 'the Company')


      European approval for silver alginate anti-microbial wound dressings


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
medical technology company, today announces that it has received approval for a
range of calcium alginate woundcare dressings containing ionic silver technology
allowing them to be sold throughout Europe.

These products have already been approved by the Food and Drug Administration
(FDA) for sale in the US and have been launched by a number of AMS' US partners
during 2005.  This has been instrumental in AMS strengthening its position in
the silver woundcare dressings market following the introduction of its initial
fibre-based silver alginate technology into the US in 2004 and Europe in 2005
under an exclusive, global agreement with a leading brand.

Silver is a broad spectrum anti-microbial that helps to prevent infections such
as MRSA.  In combination with alginate, a biopolymer derived from seaweed, AMS
can provide products ideally suited to the treatment of a wide variety of
chronic wounds.

The ionic silver technology allows AMS to provide selected partners an entry
into the expanding silver woundcare market, which is currently estimated at $100
million worldwide and growing in excess of 20% per year.

In parallel with the European approval process, AMS has been working with a
number of key partners on product launch plans. Initial market introductions are
now expected to follow during the second half of 2006.

Commenting on this announcement Dr. Don Evans, Chief Executive of AMS, stated:

'I am delighted that this product range will now be available in Europe allowing
us to further strengthen our presence in the dynamic silver market.  We are well
positioned with a wide range of products and partners on a global basis to
capitalise on the increasing trend towards using anti-microbial dressings to
help protect wounds against infection.  This is a key element of the Company's
organic growth strategy.'


For further information, please contact:

Advanced Medical Solutions Group plc                   Tel : [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications                                Tel: [phone]
Mark Court, Mary-Jane Johnson


Notes to Editors:

Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $13 billion global woundcare market.

Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.

In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS' resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives that offer benefits over sutures and
staples for closing wounds sold direct to hospitals or through distributors.

AMS' technology and products currently serve the majority of the key global
markets and strategic partners.



                      This information is provided by RNS
            The company news service from the London Stock Exchange